Evidence map›Paper›PMID 42068262›Full record

Observational studyTechnology in cancer research & treatment

Artificial Intelligence in Radiation Treatment Planning: A Survey-Based Observational Study From A Cancer Centre in Nigeria.

Adewumi O Alabi, Foaud Emadelden, Victoria Ainsworth, Victor Isibor, Bolanle C Adegboyega, Francis Boateng, Godwin Uwagba, Eben Aje, Chidi Agbwakuru, Samuel Adeneye and 5 more

Abstract readObservational Study
In one paragraph

Observational study in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Adewumi O AlabiDepartment of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, University of Lagos, Idi-araba, Nigeria.ORCID 0000-0003-1599-9438
Foaud EmadeldenDepartment of Physics, Florida Polytechnic University, Lakeland, FL, USA.
Victoria AinsworthDepartment of Physics, University of Massachusetts Lowell, Lowell, MA, USA.
Victor IsiborOncology Department, NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-araba, Nigeria.
Bolanle C AdegboyegaDepartment of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, University of Lagos, Idi-araba, Nigeria.
Francis BoatengJohn Hopkins University, Baltimore, MD, USA.
Godwin UwagbaOncology Department, NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-araba, Nigeria.
Eben AjeOncology Department, NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-araba, Nigeria.
Chidi AgbwakuruOncology Department, NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-araba, Nigeria.
Samuel AdeneyeDepartment of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, University of Lagos, Idi-araba, Nigeria.
Mariam A BashirOncology Department, NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-araba, Nigeria.
Muhammad Y HabeebuDepartment of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, University of Lagos, Idi-araba, Nigeria.
Anthonia C SowunmiDepartment of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, University of Lagos, Idi-araba, Nigeria.
Wilfred NgwaJohn Hopkins University, Baltimore, MD, USA.
Francis A Durosinmi-EttiOncology Department, NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-araba, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionLow- and middle-income countries (LMICs) like Nigeria face rising cancer incidence and mortality, with late-stage presentation and limited resources. Only eight government-funded radiotherapy centres serve a population of 223.8 million-far below the estimated 280 radiotherapy machines required. To increase patient throughput we evaluated integration of AI auto-contouring tools to expedite treatment planning, specifically target and organ-at-risk delineation.Materials and MethodsWe performed an observational, survey-based study of radiation oncology staff at our Cancer Centre. Participants were consultant and resident oncologists and medical physicists. The survey compared time spent using AI auto-contouring versus manual contouring and collected perceptions of impact, benefits, and limitations.ResultsThirty-one staff responded: 20 (64.5%) oncologists and 11 (35.5%) medical physicists. Experience with AI varied (33% ≤ 6 months; 13% ≈2 years). Respondents reported increased confidence in planning: 11 (35%) moderate, 12 (39%) moderate-high, and 8 (26%) high. Common limitations were licence availability (20, 64.5%) and technical expertise (19, 61.3%). Most respondents (20, 65%) would recommend the tool. The principal benefit was improved workflow efficiency (25, 81%). AI-assisted planning significantly reduced planning time for most tumour sites; sites with complex anatomy showed no time benefit, reflecting the need for intensive manual correction.ConclusionDeployment of AI auto-contouring at a Nigerian cancer centre reduced planning time for most sites and improved clinician confidence, but complex anatomical regions still require detailed manual oversight and additional AI training. AI tools can increase throughput in LMIC radiotherapy services, though licensing, infrastructure, and training barriers exist and must be addressed to ensure safe implementation. Future work should include multi-centre validation, formal inter-rater reliability assessment, and prospective patient-level outcome evaluation and cost-effectiveness analyses.

Indexed as

Artificial IntelligenceNeoplasmsRadiotherapy Planning, Computer-AssistedCancer Care FacilitiesHumansNigeriaRadiation OncologySurveys and Questionnairesartificial intelligencecontouringoncologyradiation treatment

Identifiers

PMID42068262
PMCPMC13153477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.